Highlights of This Issue 6953

SPECIAL FEATURES

CCR Translations 6955

MAGE: The Spell Is Broken
Katayoun Rezvani
See article p. 7058

CCR Drug Updates 6958

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Evan J. Lipson and Charles G. Drake

Molecular Pathways 6963

Novel Insights into the Role of Interleukin-27 and Interleukin-23 in Human Malignant and Normal Plasma Cells
Nicola Giuliani and Irma Airoldi

Perspective 6971

DNA Cytometry Testing for Cervical Cancer Screening: Approaches and Reporting Standards for New Technologies
Graham A. Colditz and John Crowley

Reviews 6973

DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Shadia Jalal, Jennifer N. Earley, and John J. Turchi

Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Jessica Godin-Ethier, Laila-Aicha Hanafi, Ciriaco A. Piccirillo, and Réjean Lapointe

HUMAN CANCER BIOLOGY

Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase 1
Trisha R. Sippel, Jason White, Kamalika Nag, Vadim Tsvankin, Marcia Klaassen, B.K. Kleinschmidt-DeMasters, and Allen Waziri 6992

Novel Chromosomal Rearrangements and Break Points at the 16q22 in Salivary Adenoid Cystic Carcinoma: Association with MYB–NFIB Chimeric Fusion, MYB Expression, and Clinical Outcome

Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma
David Z. Chang, Ying Ma, Baoan Ji, Huamin Wang, Defeng Deng, Yan Liu, James L. Abbazese, Yongjun Liu, Craig D. Logsdon, and Patrick Hwu

Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis

Serum Galectin-2, -4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Hannah Barrow, Xiuli Guo, Hans H. Wandall, Johannes W. Pedersen, Bo Fu, Qicheng Zhao, Chen Chen, Jonathan M. Rhodes, and Lu-Gang Yu 7024

Two Distinct Routes to Oral Cancer Differing in Genome Instability and Risk for Cervical Node Metastasis
CANCER THERAPY: PRECLINICAL

7047  Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
Yuhuan Li, Li-Xin Wang, Puixi Pang, Zhihua Cui, Sandra Aung, Daniel Haley, Bernard A. Fox, Walter J. Urba, and Hong-Ming Hu

7058  Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4
Conrad R. Cruz, Ulrike Gerdemann, Ann M. Leen, Jessica A. Shafer, Stephanie Ku, Benjamin Tzou, Terzah M. Horton, Andrea Sheehan, Amanda Copeland, Anas Younes, Cliona M. Rooney, Helen E. Heslop, and Catherine M. Bollard
See commentary p. 6955

7067  Therapeutic Implications for the Induced Levels of Chk1 in Myc-Expressing Cancer Cells

7080  Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies

7093  Synergistic Activity of Fenretinide and the Bel-2 Family Protein Inhibitor ABT-737 against Human Neuroblastoma
Hua Fang, Theresa M. Harned, Ondrej Kalous, Vanessa Maldonado, Yves A. DeClerck, and C. Patrick Reynolds

7105  Reduced miR-128 in Breast Tumor–Initiating Cells Induces Chemotherapeutic Resistance via Bmi-1 and ABCC5
Yinghua Zhu, Fengyan Yu, Yu Jiao, Juan Feng, Wei Tang, Herui Yao, Chang Gong, Jingjing Chen, Fengxi Su, Yan Zhang, and Erwei Song

7116  Novel Phosphoinositide 3-kinase/mTOR Dual Inhibitor, SVP-BGT225, Displays Potent Growth-Inhibitory Activity against Human Head and Neck Cancer Cells In Vitro and In Vivo
Kwang-Yu Chang, Shan-Yin Tsai, Ching-Ming Wu, Chia-Jui Yen, Bin-Fay Chuang, and Jang-Yang Chang

IMAGING, DIAGNOSIS, PROGNOSIS

7139  Genetic Variation in Inflammatory Pathways Is Related to Colorectal Cancer Survival
Anna E. Coghill, Polly A. Newcomb, Elizabeth M. Poole, Carolyn M. Hutler, Karen W. Makar, Dave Duggan, John D. Potter, and Cornelia M. Ulrich

7148  A Hypermethylated Phenotype Is a Better Predictor of Survival than MGMT Methylation in Anaplastic Oligodendrogial Brain Tumors: A Report from EORTC Study 26951
Martin J. van den Bent, Lonneke A. Gravendeel, Thierry Gorlia, Johan M. Kros, Larisa Lapre, Pieter Wesseling, Johannes L. Teepen, Ahmed Idbaih, Marc Sanson, Peter A.E. Sillevis Smitt, and Pim J. French

CANCER THERAPY: CLINICAL

7156  Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
Ferry A.L.M. Eskens, Maja J.A. de Jonge, Pankaj Bhurgava, Toshiyuki Ise, Monette M. Cotreau, Brooke Esteves, Kunihiko Hayashi, Herman Burger, Maarten Thomeer, Leni van Doorn, and Jaap Verweij

7164  A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer
Mahsa Mohibtash, Kwong-Yok Tsang, Ravi A. Madan, Ngar-Yee Huen, Diane J. Poole, Caroline Jochems, Jacqu in Jones, Theresa Ferrara, Christopher R. Heery, Philip M. Arlen, Seth M. Steinberg, Mary Pazdur, Myrna Rauchhorst, Elizabeth C. Jones, William L. Dahut, Jeffrey Schlim, and James L. Gulley
GLIPR1 Tumor Suppressor Gene Expressed by Adenoviral Vector as Neoadjuvant Intraprostatic Injection for Localized Intermediate or High-Risk Prostate Cancer Preceding Radical Prostatectomy
Guru Sonpavde, Timothy C. Thompson, Rajul K. Jain, Gustavo E. Ayala, Shinji Kurosaka, Kohji Edamura, Ken-Ichi Tabata, Chengzhen Ren, Alexei A. Goltsov, Martha P. Mims, Teresa G. Hayes, Michael M. Ittmann, Thomas M. Wheeler, Adrian Gee, Brian J. Miles, and Dov Kadmon

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437
Monica M. Reinholz, Kathleen A. Kitzmann, Kathleen Tenner, David Hillman, Amylou C. Dueck, Timothy J. Hobday, Donald W. Northfelt, Alvaro Moreno-Aspitia, Vivek Roy, Betsy LaPlant, Jake B. Allred, Philip J. Stella, Wilma L. Lingle, and Edith A. Perez

ABOUT THE COVER

Human melanoma xenografts of UACC903 cells with activated BRAF mutation (V600E) were either untreated or treated with vehicle (DMSO) or the compounds riluzole, sorafenib, or riluzole with sorafenib. Upon termination of the experiment, the remaining tumors were excised and stained with activated caspase-3. This image is vehicle control. For details, see the article by Lee and colleagues on page 7080 of this issue.